This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

ViroPharma Presents New Cinryze® (C1 Esterase Inhibitor [human]) Data On Site Of Care And Adherence At The 2012 Academy Of Managed Care Pharmacy Educational Conference

The most common adverse reactions in clinical trials associated with Cinryze were rash, headache, nausea, and vomiting. Adverse events of sinusitis and upper respiratory infection also were observed in clinical trials. There were no serious adverse reactions in the randomized, placebo controlled crossover routine prophylaxis study. The only serious adverse reaction observed in clinical studies of Cinryze was cerebrovascular accident. Please visit http://www.viropharma.com/products/cinryze.aspx for the full U.S. Prescribing Information; the prescribing information for other countries can be found at www.viropharma.com.

About Hereditary Angioedema (HAE)

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unregulated, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,500 people with HAE in the United States and at least 10,000 people in the European Union.

For more information on HAE, visit the U.S. HAE Association's website at
www.haea.org and the HAEi's (International Patient Organization for C1 Inhibitor Deficiencies) website at
www.haei.org.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, Friedreich's Ataxia, and adrenal insufficiency, cytomegalovirus (CMV); and recurrent
C. difficile infection (CDI). Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures, adrenal insufficiency and
C. difficile-associated diarrhea (CDAD); for full U.S. prescribing information on our products, please download the package inserts at
http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at
www.viropharma.com.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site,
www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.